Will there be a case of polio in the USA this year?
$0.00
1
1
Will there be a case of polio in the USA this year?
$0.00
1
1
AI Analysis
Trader mode: Actionable analysis for identifying opportunities and edge
About This Event
In 2026 If there are above 0 cases of polio in the United States in 2026, then the market resolves to Yes. Early close condition: This market will close and expire early if the event occurs. This market will close and expire early if the event occurs.
What Prediction Markets Are Forecasting
Prediction markets give this roughly a 13% chance, or about a 1 in 8 shot. That means traders think a US polio case in 2026 is unlikely, but not impossible. It's the kind of probability that feels uncomfortable if you're a public health official, because it's low enough to seem manageable but high enough to keep people worried.
The market resolves to Yes if there's even a single confirmed case, anywhere in the country. That's a low bar. One case, regardless of whether it's vaccine-derived or wild, and the market pays out.
Why the Market Sees It This Way
Polio was declared eliminated in the US back in 1979, and for decades the country stayed that way. Then in 2022, a young adult in Rockland County, New York contracted vaccine-derived polio, the first US case in nearly a decade. That shocked a lot of people, and it's part of why this market exists at all.
There are a few forces pushing the odds up. Vaccination rates among kindergartners have slipped in recent years, falling below the 95% threshold that public health experts consider necessary for herd immunity. Some communities, particularly in places with pockets of vaccine hesitancy, have rates closer to 80% or lower. The virus also still circulates in parts of Africa and Asia, and global travel means it's always a plane ride away.
But the market keeps odds at just 13% because the infrastructure to catch and stop it is strong. Wastewater surveillance is far better than it was even five years ago, and the CDC monitors environmental samples across many states. The oral vaccine that caused the 2022 case is no longer used in the US, which removes the main source of vaccine-derived strains. And while some communities are under-vaccinated, most of the country retains solid immunity.
Key Dates and Events to Watch
The market closes early if a case occurs, so the main thing to watch is surveillance reports. Wastewater data gets published regularly, and a positive environmental sample would likely move the odds sharply upward before any clinical case appears.
Summer and early fall are the higher-risk windows, since that's when enteroviruses, including poliovirus, tend to circulate most. If we get through October without any detection, the odds should drift lower.
Also watch for changes in vaccination policy. If the CDC or state health departments announce new immunization requirements or catch-up campaigns, that could signal rising concern and shift the market.
How Reliable Are These Predictions?
Prediction markets have a decent track record on binary health events, though rare disease outbreaks are a tough case. The 2022 case happened with essentially no warning, and a market like this would have looked very different before that event. Markets are good at aggregating known information, but they're less reliable when the risk depends on a single unpredictable event, like an unvaccinated traveler bringing the virus in.
The 13% figure probably reflects a reasonable baseline, not a precise forecast. It's a reminder that even low-probability events deserve attention, especially when the consequences are as serious as paralysis in children.
Current Market Outlook
Kalshi traders currently price a 13% chance that at least one polio case occurs in the United States during 2026. That's roughly a 1-in-8 probability, which sounds low until you consider the history. The market is saying this is an unlikely but far from impossible scenario, and the price reflects genuine uncertainty rather than a mere formality.
The market will resolve early if a case is confirmed, meaning the 13% price acts as a real-time probability estimate that could spike dramatically the moment any case is reported.
Key Factors Driving the Odds
The baseline expectation of zero cases rests on decades of successful vaccination. The US declared polio eliminated in 1979, and the inactivated polio vaccine (IPV) series maintains herd immunity above 92% nationwide. But several cracks in that foundation explain why the market isn't pricing this closer to 1%.
First, the 2022 New York case. A single paralytic polio case in Rockland County, traced to an unvaccinated individual who contracted the virus from oral polio vaccine-derived strains circulating abroad, demonstrated that importation is possible. Wastewater surveillance in the area detected the virus in multiple counties, suggesting silent circulation among undervaccinated pockets.
Second, vaccination rates have slipped. CDC data shows kindergarten exemption rates hit 3.3% in the 2023-2024 school year, the highest on record. In some counties, MMR and polio coverage fall below 80%, well under the 95% threshold needed for robust herd immunity. The pandemic disrupted routine childhood immunizations, and recovery has been uneven.
Third, global polio circulation persists. Afghanistan and Pakistan remain endemic, and vaccine-derived poliovirus outbreaks continue across Africa and Asia. International travel means the virus is always one flight away.
What Could Change These Odds
The most obvious catalyst is a confirmed case, which would trigger early resolution. But watch for three specific signals that could shift odds before that happens.
Wastewater surveillance data from the CDC's National Wastewater Surveillance System publishes regularly. Any detection of poliovirus in a US sample would likely push the market toward 40-60% within days.
The 2025-2026 school year vaccination data, typically released in early fall, will show whether exemption rates continue climbing. A jump above 4% could add several points to the probability.
Finally, watch the global situation. If Pakistan or Afghanistan reports a major outbreak, or if vaccine-derived outbreaks in the Democratic Republic of Congo or Yemen expand, the importation risk rises. The market currently prices a 13% chance, but that number would move fast if any of these factors deteriorate.
The 13% figure is best understood as a bet on the resilience of American public health infrastructure against a virus that has been beaten before, but never fully eradicated.
AI-generated analysis based on market data. Not financial advice.
Overview
Polio, or poliomyelitis, is a highly infectious viral disease caused by the poliovirus, which primarily affects children under five years old. The virus spreads from person to person, typically through contaminated water or food, and can invade the nervous system, causing paralysis or even death. While there is no cure, safe and effective vaccines have been available since the 1950s, and global eradication efforts have reduced cases by over 99% since 1988. In the United States, routine childhood vaccination has eliminated indigenous wild poliovirus since 1979, but the disease remains a concern due to international travel and the rare use of oral polio vaccine (OPV) in other countries, which can lead to vaccine-derived poliovirus (VDPV) outbreaks. This prediction market asks whether there will be at least one case of polio in the United States in 2026. A case is defined as laboratory-confirmed poliovirus infection, including both wild-type and vaccine-derived strains, regardless of whether paralysis occurs. The market resolves to 'Yes' if any such case is reported within the calendar year. Early closure occurs if the event happens before the year ends, meaning the market will settle as soon as the first case is confirmed. Interest in this topic stems from recent events: in July 2022, a case of paralytic polio caused by vaccine-derived poliovirus type 2 was confirmed in an unvaccinated adult in Rockland County, New York, marking the first U.S. case since 2013. That case, linked to wastewater detection in several New York counties, prompted health officials to declare a state of emergency and urge vaccination. Since then, surveillance efforts have intensified, but no further cases have been reported. However, global polio outbreaks, particularly in Afghanistan, Pakistan, and parts of Africa, continue to pose a threat of importation. The probability of a U.S. polio case in 2026 depends on several factors: vaccination coverage, international travel patterns, and the effectiveness of wastewater surveillance. As of 2023, about 92% of U.S. children received the recommended polio vaccine series by age two, but pockets of under-vaccinated communities remain. The CDC's Advisory Committee on Immunization Practices (ACIP) continues to recommend routine childhood vaccination, and no changes to the schedule are anticipated. The market provides a way for forecasters to weigh these risks and express a probability that the country will see a case, which is a rare but not impossible event.
Historical Context
The United States experienced its last case of wild poliovirus in 1979, when an outbreak occurred among Amish communities in the Midwest, likely imported from the Netherlands. Since then, the country has relied on inactivated polio vaccine (IPV) exclusively, which does not carry the risk of vaccine-derived virus. However, in 2005, a cluster of vaccine-derived poliovirus infections was detected in Minnesota among unvaccinated children, though no cases of paralysis occurred. These were caused by a strain from oral polio vaccine used in another country, highlighting the importation risk. More recently, in July 2022, a 20-year-old unvaccinated man in Rockland County, New York, developed paralytic polio caused by vaccine-derived poliovirus type 2. He had not traveled internationally, suggesting local transmission. Wastewater sampling subsequently found the virus in several counties in New York, as well as in London and Jerusalem, indicating that the virus was circulating in communities with low vaccination coverage. The CDC declared the outbreak a public health emergency, and vaccination campaigns were launched. No further cases were reported, and the outbreak was declared over in 2023, but the event underscored the fragility of the U.S. polio-free status. Historically, polio was one of the most feared diseases in the U.S., with annual epidemics causing thousands of cases of paralysis. The introduction of the Salk vaccine in 1955 and the Sabin oral vaccine in 1961 led to a dramatic decline, and the last naturally occurring case was in 1979. The country transitioned to the inactivated vaccine in 2000 to eliminate any risk of vaccine-associated paralytic polio (VAPP), which occurred in about 1 in 2.4 million doses. This history shapes current policy, where vaccination rates are closely monitored, and any case is treated as a public health emergency.
Why It Matters
A single case of polio in the U.S. would be a significant public health event, signaling a failure in vaccination coverage and surveillance. It would likely trigger an immediate response, including mass vaccination campaigns, wastewater testing, and travel advisories. The economic costs would be substantial: the 2022 New York case led to millions of dollars spent on emergency response, laboratory testing, and outreach. Moreover, a case could erode public confidence in vaccines, leading to lower immunization rates for other diseases, which could have cascading health consequences. The broader impact extends beyond health. Polio is a highly visible indicator of public health preparedness. A case in 2026 would likely dominate headlines, prompting political scrutiny and debates over vaccination mandates. It could also affect international travel and trade, as other countries may impose restrictions on travelers from the U.S. if there is evidence of ongoing transmission. For the global eradication effort, a U.S. case would be a major setback, as the country is a major donor to the GPEI and a model for other nations. It would highlight the risk that polio can return even in high-income countries with strong health systems, emphasizing the need for continued vigilance worldwide.
Current Status
As of late 2025, the United States has not reported a polio case since 2022. The CDC continues to monitor wastewater for poliovirus, but no positive samples have been found since the end of the New York outbreak in 2023. Routine vaccination coverage has remained stable, though some school districts have reported lower rates due to vaccine hesitancy. The GPEI has recently launched a new strategy to eradicate polio by 2026, but progress has been slow, with ongoing outbreaks in Afghanistan and Pakistan. In the U.S., health officials are preparing for the possibility of a case by updating response plans and conducting tabletop exercises. The market is likely to stay open through 2026 unless a case is confirmed early, in which case it would close immediately.
Frequently Asked Questions
What is the difference between wild poliovirus and vaccine-derived poliovirus?
Wild poliovirus is the naturally occurring virus that has been nearly eradicated. Vaccine-derived poliovirus (VDPV) arises from the oral polio vaccine (OPV), which contains a weakened live virus that can mutate and regain the ability to cause paralysis in under-vaccinated populations. The U.S. only uses the inactivated polio vaccine (IPV), so all U.S. cases since 1979 have been vaccine-derived from virus imported from countries using OPV.
Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.
